ea0099ep413 | Adrenal and Cardiovascular Endocrinology | ECE2024
Simeoli Chiara
, M. Crescenzo Erminio
, M. Pulci Doria Augusta
, Larocca Angelica
, Di Paola Nicola
, Pivonello Claudia
, Negri Mariarosaria
, Colao Annamaria
, Pivonello Rosario
Life-long glucocorticoid (GC) treatment is needed in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, to replace GC deficiency and to control androgens excess. Multiple daily immediate-release-hydrocortisone (IR-HC), characterized by GC overexposure, peaks and troughs, is frequently associated with a suboptimal androgen control, due to ACTH overnight increase. Once daily dual-release-HC (DR-HC), approved for adrenal insufficiency and, despit...